| Code | CSB-RA801822MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to XKH-002, targeting VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1), also known as B7-H4 or B7S1. VTCN1 is an immune checkpoint protein belonging to the B7 family that functions as a negative regulator of T cell-mediated immune responses. It inhibits T cell proliferation, cytokine production, and cytotoxic activity through interactions with receptors on activated T cells. VTCN1 is minimally expressed in normal tissues but becomes significantly upregulated in various malignancies, including ovarian, lung, breast, and renal cell carcinomas, where its expression correlates with tumor progression, immune evasion, and poor clinical prognosis.
XKH-002 serves as the reference antibody for studying VTCN1-mediated immune suppression in the tumor microenvironment. This biosimilar provides researchers with a reliable tool for investigating VTCN1's role in cancer immunology, exploring immune checkpoint mechanisms, and evaluating potential therapeutic strategies targeting the B7-H4 pathway. It supports studies examining tumor-immune cell interactions and the development of novel immunotherapeutic approaches.
There are currently no reviews for this product.